{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971721",
  "id": "02971721",
  "pages": 11,
  "price_sensitive": false,
  "date": "20250723",
  "time": "0845",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1n8l91l4pnt.pdf",
  "summary": "- **Clinical Trial Updates:**  \n  - **CHM CDH17 CAR-T Trial:**  \n    - 5 patients treated (Dose Level 1 completed, Dose Level 2 commenced).  \n    - 2/4 patients showed stable disease (6 months for one, day 150 for another).  \n    - 8/8 successful GMP manufacturing runs.  \n  - **CHM CORE-NK Trial:**  \n    - Dose-finding completed; frontline AML trial commenced.  \n    - 2/3 patients achieved CRi (complete response with incomplete blood recovery).  \n    - No dose-limiting toxicities or cytokine release syndrome observed.  \n\n- **Capital & Corporate:**  \n  - **$16.6m raised** (includes $5.6m from US Family Office).  \n  - Lind facility repaid in full by July 2025.  \n  - Significant cost reductions implemented.  \n\n- **Financial Position:**  \n  - Market cap: ~$1.6B (share price: $0.005, 52-week range: $0.004\u2013$0.047).  \n  - Cash balance not explicitly stated (likely covered under capital raise).  \n\n- **Portfolio:**  \n  - 4 active Phase 1 trials across novel cell therapies.  \n  - Unique CDH17 CAR-T candidate (only one in clinical trials).  \n\n**Omitted:** Forward-looking statements, disclaimers, non-material operational details.",
  "usage": {
    "prompt_tokens": 1515,
    "completion_tokens": 300,
    "total_tokens": 1815,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T22:49:57.763416"
}